Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted chemotherapy for extracranial non-seminomatous malignant germ cell tumors in children and adolescents
2013-004039-60Phase 3Active
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of cisplatin, vinblastine, bleomycin, etoposide and ifosfamide in extragonadal germ cell cancer (EGCT) and cancer, sponsored by Centre Léon Bérard. Primary endpoint: Progression-free survival. Started Sep 2015; status: active.
02
Drugs
cisplatinvinblastinebleomycinetoposideifosfamide
03
Conditions
extragonadal germ cell cancer (EGCT)cancer
Beyond the preview
Go deeper on 2013-004039-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004039-60.